Toward optimizing patient selection for EGFR antibody therapies in metastatic colorectal cancer: outcomes and resistance features in real-world data

Toward optimizing patient selection for EGFR antibody therapies in metastatic colorectal cancer: outcomes and resistance features in real-world data

Background: Patients with metastatic colorectal cancer (mCRC) with RAS- or BRAF-mutant tumors do not benefit from epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) therapy. Among patients with RAS/BRAF wild-type (WT) tumors, a substantial portion still do not benefit from EGFR mAb tr...

Full description

Saved in:
Bibliographic Details
Main Authors: M.J. Emmett, J.C.F. Quintanilha, R.P. Graf, G. Li, H. Tukachinsky, A.B. Schrock, S. Morley, V.A. Fisher, G.R. Oxnard, C.H. Lieu, P.A. Myer, S.J. Klempner
Format: Article
Language:English
Published: Elsevier 2024-06-01
Series:ESMO Real World Data and Digital Oncology
Subjects:
colorectal cancer
real-world data
comprehensive genomic profiling
next-generation sequencing
EGFR
Online Access:http://www.sciencedirect.com/science/article/pii/S2949820124000146
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2949820124000146

Similar Items